VERVE-102: A Revolutionary Gene-Editing Therapy for Cholesterol Management

VERVE-102 is an experimental gene-editing therapy that shows promise in significantly lowering 'bad' LDL cholesterol with a single treatment. Developed by Verve Therapeutics and acquired by Eli Lilly, this innovative therapy targets the PCSK9 gene in the liver, potentially transforming the management of high cholesterol and heart disease. Early trial results indicate substantial reductions in LDL cholesterol levels, sustained for up to 18 months. As heart disease remains a leading cause of death globally, VERVE-102 could offer a new solution for patients struggling with traditional cholesterol medications. With ongoing studies, this therapy may pave the way for a revolutionary approach to cardiovascular health.

By Narendra Chaudhary Jun 8, 2026, 17:19 IST

Introduction to VERVE-102

VERVE-102, an innovative experimental therapy, is creating a buzz in cardiovascular medicine as early clinical trials indicate it can significantly reduce 'bad' LDL cholesterol with just one treatment. This gene-editing therapy, developed by Verve Therapeutics and now under Eli Lilly and Company, has the potential to revolutionize the management of high cholesterol and heart disease risk.

Recently, the promising results from the Phase 1b Heart-2 trial were showcased at the European Atherosclerosis Society Congress and published in the The New England Journal of Medicine.

Understanding VERVE-102

What is VERVE-102?

VERVE-102 is a one-time gene-editing treatment aimed at permanently lowering low-density lipoprotein cholesterol (LDL-C), often referred to as 'bad cholesterol.' Unlike traditional daily statin medications or repeated injections, this therapy is designed to be administered through a single intravenous infusion.

The therapy specifically targets the PCSK9 gene in the liver using advanced in vivo base-editing technology. Research has shown that individuals with inactive PCSK9 genes naturally maintain low LDL cholesterol levels and have a reduced risk of heart attacks throughout their lives. VERVE-102 aims to replicate this protective effect by disabling the PCSK9 gene after just one treatment.

Early Trial Results Show Promise

Promising Early Trial Results

The ongoing Heart-2 Phase 1b study is assessing VERVE-102 in adults diagnosed with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease (CAD), both of which are associated with dangerously elevated cholesterol levels and heightened cardiovascular risk.

In an interim analysis involving 35 participants, researchers noted significant decreases in circulating PCSK9 protein and LDL cholesterol across all tested doses. At the highest dose of 1.0 mg/kg, participants experienced up to an 88% reduction in PCSK9 protein and approximately 62% reduction in LDL cholesterol. Notably, these reductions were sustained for up to 18 months following a single infusion, suggesting that VERVE-102 may offer long-lasting cholesterol control without the need for lifelong medication.

Potential to Replace Statins

Could This Replace Daily Statins?

Currently, statins are the most commonly prescribed treatment for lowering cholesterol and preventing heart disease. However, many patients face challenges with long-term adherence due to side effects, costs, or the necessity of daily medication. Experts believe that gene-editing therapies like VERVE-102 could transform cardiovascular treatment from chronic disease management to a potential one-time intervention.

Cardiologists suggest that this therapy may provide a new option for patients who struggle to maintain LDL cholesterol control with existing medications.

Safety Profile of VERVE-102

Safety and Side Effects

So far, VERVE-102 has demonstrated a favorable safety profile. Researchers reported:

No serious adverse events related to the treatment

No dose-limiting toxicities

Mild infusion-related reactions and fatigue in some participants

All participants completed the planned treatment without withdrawing from the study.

Significance of VERVE-102

Why Does This Matter?

Heart disease is one of the leading causes of death worldwide, and familial hypercholesterolemia affects approximately 1 in 200 to 250 individuals globally. Many people with inherited high cholesterol develop premature coronary artery disease despite aggressive treatment efforts. The US Food and Drug Administration has granted Fast Track designation to VERVE-102 due to its potential to meet a significant unmet medical need.

While larger Phase 2 studies are necessary before approval, researchers are optimistic that VERVE-102 could represent a significant advancement in gene-editing medicine and cholesterol management. If future trials continue to demonstrate strong efficacy and safety, a single infusion to permanently lower LDL cholesterol may soon become a reality.